Zurzuvae® (zuranolone)
for Depression/Major Depressive Disorder

Zurzuvae (zuranolone) is the first FDA-approved oral treatment for postpartum depression (PPD). This rapid-acting, once-daily capsule is taken for 14 days and provides faster symptom relief than traditional antidepressants. PPD, which can develop after childbirth or late in pregnancy, causes severe emotional distress and may impact a mother’s ability to bond with her baby, affecting the child's development.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Depression/Major Depressive Disorder - MDD